Skip to main content

Advertisement

We're creating a new version of this page. See preview

  • Original article
  • Open Access

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1, 2 and
  • 1Email author
Cancer Communications201838:50

https://doi.org/10.1186/s40880-018-0319-7

©  The Author(s) 2018

  • Received: 7 December 2017
  • Accepted: 11 July 2018
  • Published:

Abstract

Background

In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells.

Methods

The growth-inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting.

Results

In MTT and clonogenic assays, phenformin was > 10-fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone.

Conclusions

Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib.

Keywords

  • Phenformin
  • Gefitinib
  • Bladder cancer
  • AMPK
  • EGFR

Introduction

The biguanide metformin is widely used as a first-line oral hypoglycemic drug against diabetes [1]. It is well tolerated and safe, with well-characterized pharmacokinetics [2, 3]. Accumulating evidence suggest that metformin could also improve the survival of patients with colorectal, breast cancer, or prostate cancer [4–6]. In fact, it may lower the risk of certain types of cancer [7]. However, obtaining approval from regulatory authorities such as the US Food and Drug Administration to use metformin as an anticancer drug has proven challenging because effective drug concentrations are much higher than anti-diabetic doses. Such high concentrations in the blood are not achievable via conventional oral administration [8, 9].

Phenformin is a derivative of metformin, with higher anticancer potency at lower doses [10–12]. Phenformin is more lipophilic than metformin, and does not require cell-surface transporters such as Oct1 to enter cells. This feature makes phenformin potentially more versatile than metformin for targeting cancer tissues, since Oct1 is not expressed in all tissues [13, 14]. Here we examined whether phenformin shows efficacy against bladder cancer [15–17]. In a previous study, we showed that the combination of metformin and the epidermal growth factor receptor (EGFR) inhibitor gefitinib produces cytotoxic effects in bladder cancer cells [9]. Gefitinib is effective as adjuvant treatment of primary bladder cancer [18]. Metformin is synergistic with gefitinib [19]. In the present study, we examined the anticancer effects of phenformin alone and in combination with gefitinib. Our goal was to determine whether phenformin could inhibit bladder cancer cell growth effectively at lower doses than metformin. Since metformin produces antitumor effects by activating adenosine monophosphate (AMP)-activated protein kinase (AMPK) and subsequent inhibition of the mTOR signaling [20–22], we also examined whether phenformin could inhibit cancer growth by activating AMPK [2, 23].

Materials and methods

Reagents

Phenformin (Aladdin Chemistry, Shanghai, China) was prepared in a range of concentrations in culture medium. Gefitinib (Selleck-Biotool, Shanghai, China) was prepared as a stock solution of 5 mmol/L in DMSO. Antibodies against the following target proteins were obtained from Cell Signaling (Beverly, MA, USA): total p70 S6 kinase, phospho-p70 S6 kinase (Thr389), total AMPKα, phospho-AMPKα (Thr172), total mTOR, phospho-mTOR (Ser2448), total 4E-BP1, phospho-4EBP1, total EGFR, phospho-EGFR and β-actin.

Cell lines and culture conditions

The mouse bladder cancer cell line MB49 and the human bladder cancer cell lines T24 and UMUC3 were generously provided by Dr. P. Guo of the Institute of Urology at Xi’an Jiaotong University (Xi’an, Shaanxi, China) [9]. All cell lines were cultured in DMEM (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone) and 1% penicillin–streptomycin. Cultures were incubated at 37 °C in humidified air containing 5% CO2.

Cell viability assay

Cell viability was assessed using a tetrazolium-based assay. Briefly, cells were seeded at 8 × 103 per well in 96-well culture plates and incubated in medium containing 10% FBS. At 24 h later, cells were treated for 48 h with different concentrations of phenformin alone or in combination with gefitinib. The tetrazolium salt of MTT (50 μL; Sigma) was dissolved in Hank’s balanced salt solution to a concentration of 2 mg/mL, and added to each well. The plates were incubated another 5 h. The medium was aspirated from each well, DMSO (150 μL; Sigma) was added to dissolve formazan crystals, and absorbance was measured using a microplate reader (Biotek, SYNERGY HTX, VT, USA) at 490 nm (against reference absorbance at 630 nm). Dose–response curves were generated and used to calculate the half-maximal inhibitory concentration (IC50) using SPSS 16.0 (IBM, Chicago, IL, USA).

Clonogenic assay

Briefly, 8 × 103 cells were seeded into 24-well dishes in 0.5 mL of medium. At 24 h, cells were treated with different concentrations of phenformin alone or combined with gefitinib for a further 6–8 day period in medium containing 10% FBS. Cells were fixed with 10% formaldehyde, stained with 0.1% crystal violet. Absorbance was measured using a microplate reader (Biotek) at 550 nm wavelength. Colony formation images were captured under a microscope (DFC450C; Leica, Wetzlar, Germany).

Cell migration

Cells (5 × 103) were seeded into 6-well plates and allowed to reach confluence. The monolayer was scratched using a cocktail stick. Cells were incubated with serum-free DMEM medium for different time periods before capturing the digital images with a DFC450C microscope (Leica). Wound closure was determined by measuring the migrated distance of cells from the 0 h using Image J (US National Institutes of Health, Bethesda, MD, USA). Experiments were repeated three times.

Apoptosis

In one set of experiments, apoptosis was assessed using fluorescence microscopy. Cells (1.2 × 104) were seeded into 96-well plates. After 24 h, cells were treated with phenformin alone or with gefitinib for 24 h. Then the cells were incubated at room temperature in the dark for 15 min with 100 μL binding buffer, 1 μL FITC-conjugated Annexin V (MultiSciences Biotech, Hangzhou, China) and 1 μL of propidium iodide (MultiSciences Biotech). Cells were observed under a DFC450C fluorescence microscope (Leica).

Apoptosis was assessed using flow cytometry in a separate experiment. Briefly, cells treated with the different drug combinations were harvested with trypsinization, washed twice with phosphate-buffered saline (PBS), and resuspended in binding buffer to 1 × 106 cells/mL. Then 5 μL of Annexin V-FITC and 10 μL of propidium iodide were added to 100 μL of cell suspension, incubated for 30 min at room temperature in the dark, and then mixed with 400 μL of binding buffer. Within 30 min, labeled cells were counted by flow cytometry on a FACS Calibur flow cytometer [excitation wavelength, 488 nm; emission wavelengths, 530 nm (FL-1 channel, FITC) and 670 nm (FL-3 c3 channel, propidium iodide)]. Data were analyzed using Cell Quest software (Becton–Dickinson). Non-apoptotic cells were defined as those negative for Annexin-V and propidium iodide; necrotic/late apoptotic cells as those positive for both labels; and early apoptotic cells as those positive for Annexin V but negative for propidium iodide.

Western blotting

Proteins were fractionated by SDS-PAGE, transferred to membranes, and then incubated overnight at 4 °C with different primary antibodies described in Reagents section above (Cell Signaling, Beverly, MA, USA) in buffer containing bovine serum albumin (BSA). Membranes were washed with TBS containing 0.05% Tween-20, blotted with secondary antibody for 1 h at room temperature, then washed again three times. Pierce Super Signal chemiluminescent substrate (Rockford, IL, USA) was added, and the blot was imaged immediately on a Chemi Doc system (Bio-Rad, Hercules, CA, USA) and a Perfection V500 camera (Epson). Band intensities were quantified using Image J.

Statistical analyses

All data are presented as mean ± SD. Statistical analysis was performed using SPSS 16.0. Differences between groups were assessed for significance using Student’s t test for experiments involving only two groups and using ANOVA and the least significant difference (LSD) test for experiments involving more than two groups. Graphs were generated using GraphPad Prism 6.0. Two levels of statistical significance were considered: *P < 0.05 and #P < 0.01.

Results

Phenformin inhibits bladder cancer cell proliferation

Phenformin inhibited cell proliferation within a concentration range of 0.02–8 mmol/L in a concentration-dependent manner (Fig. 1). The most sensitive cell line was UMUC3 (IC50, 0.25 mmol/L); the most resistant cell line was T24 ((IC50, 0.87 mmol/L; Table 1).
Fig. 1
Fig. 1

Effect of phenformin on bladder cancer cell proliferation. Viability of T24, UMUC3 and MB49 cells was assessed after 48-h exposure to phenformin at concentrations ranging from 0 to 8 mmol/L using a tetrazolium-based assay. Results are the mean ± SD of three independent experiments

Table 1

IC50 values for phenformin against bladder cancer cell lines

 

Bladder cancer cell line

MB49

T24

UMUC3

IC50 (mmol/L)

0.57

0.97

0.25

Phenformin synergistically potentiates the anti-proliferative effects of gefitinib

Consistent with our previous study [9], gefitinib did not affect the growth of the cell lines (Fig. 2, Table 2), but interacted synergistically with phenformin to inhibit cancer cell growth (Fig. 3).
Fig. 2
Fig. 2

Effect of gefitinib on bladder cancer cell proliferation. Viability of T24, UMUC3 and MB49 cells was assessed after 48-h exposure to gefitinib at concentrations ranging from 0 to 80 µmol/L using a tetrazolium-based assay. Results are the mean ± SD of three independent experiments

Table 2

IC50 values for gefitinib against bladder cancer cell lines

 

Bladder cancer cell line

MB49

T24

UMUC3

IC50 (µmol/L)

1.6

30.1

17

Fig. 3
Fig. 3

Effect of gefitinib combined with phenformin on bladder cancer cell proliferation. a Gefitinib combined with phenformin inhibited MB49 proliferation synergistically. Above: Cell viability was assessed after 48-h treatment with gefitinib (0, 0.125, 0.25, 0.5, or 1 µmol/L) alone or combined with phenformin (0.125, 0.25, or 0.5 mmol/L). Below: The combination index (CI) assessing synergy between the two drugs was calculated. b Gefitinib combined with phenformin inhibited T24 proliferation synergistically. Above: Cell viability was assessed after 48-h treatment with gefitinib (0, 1.25, 2.5, 5, or 10 μM) alone or combined with phenformin (0.125, 0.25, or 0.5 mmol/L). Below: The combination index (CI) assessing synergy between the two drugs was calculated. CI = 1 denotes additivity; CI > 1, antagonism; CI < 1, synergism. CI values in nearly all combinations were less than 0.5, indicating moderately strong synergism. c Gefitinib combined with phenformin inhibited UMUC3 proliferation synergistically. Above: Cell viability was assessed after 48-h treatment with gefitinib (0, 1.25, 2.5, 5, or 10 µmol/L) alone or combined with phenformin (0.0125, 0.025, or 0.05 mmol/L). Below: The combination index (CI) assessing synergy between the two drugs was calculated. Results are the median of five independent experiments

Phenformin alone or combined with gefitinib suppresses colony formation

Phenformin alone inhibited colony formation in all three cell lines at concentrations of 0–0.5 mmol/L (Fig. 4). At a concentration as low as 0.125 mmol/L, phenformin significantly reduced the numbers of T24 and MB49 colonies. The most sensitive cell line was UMUC3. Combining phenformin with gefitinib led to an even greater inhibition (Fig. 5).
Fig. 4
Fig. 4

Evaluation of colony suppression by phenformin on three bladder cancer cell lines. a–c Cells were treated for 7 days with phenformin alone, and then stained with crystal violet to allow colony counting. MB49 and T24 cells were treated with 0–0.5 mmol/L phenformin; UMUC3 cells, with 0–0.05 mmol/L. Wells were photographed using an inverted microscope (magnification, ×10). Control wells contained no drug. d–f Quantification of the experiments conducted in panels (a–c). Wells were scanned at a wavelength of 550 nm. Results are the mean ± SD of five independent experiments. *P < 0.05, #P < 0.01 vs. control (two-tailed t test)

Fig. 5
Fig. 5

Evaluation of colony suppression by phenformin combined with gefitinib. a–c Cells were treated for 7 days with phenformin alone, gefitinib alone or both, and then stained with crystal violet to allow colony counting. MB49 cells were treated with 0.125 mmol/L phenformin, 0.125 µmol/L gefitinib, or both; T24 cells, with 0.125 mmol/L phenformin, 1 µmol/L gefitinib, or both; UMUC3 cells, with 0.0125 mmol/L phenformin, 1 µmol/L gefitinib, or both. Wells were photographed using an inverted microscope (magnification, ×10). Control wells contained no drug. d–f Quantification of the experiments conducted in panels (a–c). Wells were scanned at a wavelength of 550 nm. Results are the mean ± SD of five independent experiments. *P < 0.05, #P < 0.01 vs. control (two-tailed t test)

Phenformin alone or combined with gefitinib inhibits cell migration

In the scratch assay, phenformin significantly increased the cell-free area at 24 h (P < 0.05 vs. control, Fig. 6). The assay was repeated by treating MB49 cells with 0.05 mmol/L phenformin alone, 1.25 μmol/L gefitinib alone or their combination. In addition, the assay was repeated by treating T24 and UMUC3 cells with 0.05 mmol/L phenformin alone, 10 μmol/L gefitinib alone or their combination. The combination of drugs inhibited migration to a greater extent than either drug alone (Fig. 7).
Fig. 6
Fig. 6

Phenformin impaired cellular migration in wound healing assays. a–c Photographs showing gaps in the scratched regions of MB49, T24, and UMUC3 monolayers subsequently treated with the indicated drug. Control wells received no drug. d–f Wound closure distances measured from the experiments shown in panels (a–c). Results are mean ± SD of three independent experiments. *P < 0.05, #P < 0.01 vs. control

Fig. 7
Fig. 7

Phenformin treatment combined with gefitinib impaired cellular migration in wound healing assays. a–c Photographs showing gaps in the scratched regions of MB49, T24, and UMUC3 monolayers subsequently treated with the indicated drug alone or combination. Control wells received no drug. d–f Wound closure distances measured from the experiments shown in panels (a–c). Results are mean ± SD of three independent experiments. *P < 0.05, #P < 0.01 vs. control

Phenformin alone or combined with gefitinib activates AMPK signaling pathways

All three cell lines were treated with phenformin at doses of 0–0.5 mmol/L for 36 h, and cell lysates were analyzed by Western blotting for levels of p-AMPK (T172), p-mTOR (S2448) and the mTOR downstream effectors p70S6K and p4EBP1 (Fig. 8). Phenformin activated AMPK and led to lower levels of phosphorylated 4EBP1 and p70S6K. In our previous work, we observed similar effects with metformin but only at much higher concentrations [9].
Fig. 8
Fig. 8

Effects of phenformin on AMPK intracellular signaling pathways. Western blot analysis was used to examine the levels of total (t) and phosphorylated (p) forms of various signaling proteins in MB49, T24, and UMUC3 cells treated with phenformin at various concentrations. Control cells received no drugs. a–c Western blots of p-AMPK, p-mTOR, p-p70S6K, p-4EBP1, t-AMPK, t-mTOR, t-p70S6K and t-4EBP1. β-actin was included as a loading control. d–f Relative levels of various proteins. Results are mean ± SD. *P < 0.05, #P < 0.01 vs. control

AMPK signaling pathway activation was much higher upon treatment with phenformin in combination with gefitinib than with either drug alone (Fig. 9). In our previous work [9], we achieved strong synergy with the combination of metformin and gefitinib, but at a metformin concentration eightfold higher than the phenformin concentration in the present work. The synergy between phenformin and gefitinib was greatest for the UMUC3 cell line.
Fig. 9
Fig. 9

Effects of the combination of gefitinib with phenformin on AMPK signaling pathways. Western blot analysis was used to examine total (t) and phosphorylated (p) forms of various signaling proteins in MB49, T24, and UMUC3 cells treated with phenformin, gefitinib or their combination. Control cells received no drugs. a–c Western blots of p-AMPK, p-mTOR, p-p70S6K, p-4EBP1, t-AMPK, t-mTOR, t-p70S6K and t-4EBP1. β-actin was included as a loading control. d–f Relative levels of various proteins. Results are mean ± SD. *P < 0.05, #P < 0.01 vs. control

Phenformin alone or combined with gefitinib inhibits the EGFR signaling pathways

In our previous work [19], we showed that metformin and gefitinib cooperatively inhibited bladder cancer growth by inhibiting EGFR signaling. Here we examined whether the same was true for the combination of phenformin and gefitinib (Figs. 10 and 11). We found that phenformin alone or together with gefitinib inhibited EGFR signaling at concentrations eightfold lower than used in our previous work.
Fig. 10
Fig. 10

Effects of phenformin on EGFR phosphorylation. Western blot analysis was used to examine total (t) and phosphorylated (p) forms of EGFR in MB49, T24, and UMUC3 cells treated with phenformin at various concentrations s. a–c p-EGFR and t-EGFR. β-actin was included as a loading control. d–f Relative levels of phosphorylated EGFR. Results are mean ± SD. *P < 0.05, #P < 0.01 vs. control

Fig. 11
Fig. 11

Effects of the combination of gefitinib with phenformin on EGFR phosphorylation. Western blot analysis was used to examine total (t) and phosphorylated (p) forms of EGFR in MB49, T24, and UMUC3 cells treated with phenformin, gefitinib or their combination. a–c Western blotting of p-EGFR and t-EGFR. β-actin was included as a loading control. d–f Relative levels of phosphorylated EGFR. Results are mean ± SD. *P < 0.05, #P < 0.01 vs. control

Phenformin alone or combined with gefitinib promotes apoptosis

Either phenformin or gefitinib alone substantially increased the proportion of apoptotic cells in all three cell lines (Fig. 12). The combination of the two drugs led to a much higher proportion of apoptotic cells than either drug alone.
Fig. 12
Fig. 12

Effect of gefitinib combined with phenformin on apoptosis. a–c Fluorescence micrographs to assess FITC and propidium iodide staining of MB49, T24, and UMUC3 cell lines treated with the indicated drugs. Control cells received no drugs. d–f Representative flow cytometry scatter plots showing propidium iodide (y axis) and Annexin V-FITC (x axis) staining. Quantitation of flow cytometry experiments. Results are the mean ± SD of three independent experiments. *P < 0.05, #P < 0.01 vs. control

Discussion

The results from the current study showed that phenformin, either alone or in combination with gefitinib, could produce antitumor effects in bladder cancer cells. Phenformin may be better suited for this purpose than its parent compound metformin. Metformin has been shown to inhibit bladder cancer cell proliferation in vitro and in vivo [9], but only at concentrations that are difficult or impossible to achieve in human subjects. In addition, a trial in patients with type 2 diabetes failed to find an association between the use of metformin and decreased incidence of bladder cancer [24].

Our results in the present study suggest that phenformin can substantially inhibit bladder cancer cell proliferation, colony formation and migration at much lower concentrations than metformin. For example, phenformin inhibited colony formation in the most sensitive UMUC3 cell line by > 100-fold greater than metformin at tenfold lower concentrations. These cellular effects at much lower phenformin concentrations were associated with the activation of AMPK signaling and inhibition of EGFR signaling. Our findings extended the literature of phenformin antitumor activities from breast cancer cells and other cell types to bladder cancer [25].

Based on previous work [19, 26], we speculate that the much higher therapeutic efficiency of phenformin over metformin can be attributed to higher lipophilicity of phenformin and the fact that phenformin does not require organic cation transporters to enter cells [27]. Such transporters are not expressed in all tissues. As a result, phenformin can readily enter a broader range of cell types.

Metformin and phenformin increase AMPK activity without increasing the AMP/ATP ratio [28], which is important for the anti-cancer mechanism of both biguanides [9]. Tumorigenesis is a multistep process and tumor cells often undergo metabolic re-programming to support the rapid growth [29]. Targeting metabolic re-programming using biguanides represents a promising therapeutic strategy in cancer. In the present study, we showed that phenformin activates AMPK phosphorylation in bladder cancer cells. We also demonstrated that phenformin inactivates two proteins that act downstream of AMPK, namely 4EBP1 and p70S6K. These results suggest that phenformin may induce apoptosis in bladder cancer cells via the AMPK/mTOR/p70S6K axis.

Targeting multiple sites, such as with phenformin and gefitinib is generally superior to single-target anticancer therapy. The synergistic action observed in the current study probably reflects mechanistic “crossover”: we showed here that phenformin inhibits EGFR signaling in a dose-dependent manner, and we previously showed that gefitinib can activate AMPK signaling [19]. As a result of this synergy, the combination of the two drugs inhibited bladder cancer cell proliferation and colony formation while stimulating apoptosis to a much greater extent than either drug alone.

Our in vitro findings here should be verified and extended in preclinical animal studies. In addition to efficacy, whether the combination therapy is associated with toxic effects in vivo should be examined. Despite these limitations, the present work provides evidence that phenformin can effectively inhibit bladder cancer growth by activating AMPK signaling and inhibiting EGFR signaling. The results also encourage future studies to explore phenformin on its own and combined with gefitinib as multi-targeted anticancer therapy.

Declarations

Authors’ contributions

YH analyzed the data and wrote the paper. YH, SZ and TT prepared and calculated the data. QS and CH participated in sample and data collection. KOD, JD, MP processed and analyzed the data. XY contributed to study design and manuscript review. All authors read and approved the final manuscript.

Acknowledgements

We deeply appreciate the help of our colleagues at Hunan Normal University.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets analyzed in the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported by grants to X.Y. from the Hunan Natural Science Foundation (2016JJ2187), the Key Project of Hunan Province 2016 (2016JC2036) and Start-up Funds of the Key Laboratory of Study and Discovery of Targeted Small Molecules of Hunan Province (2017TP1020); and by a grant to M.P. from the Chinese National Science Foundation (81703008).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Key Laboratory of Study and Discovery of Targeted Small Molecules of Hunan Province and Department of Pharmacy in the School of Medicine and Laboratory of Animal Nutrition and Human Health, Hunan Normal University, Changsha, 410013, Hunan, P. R. China
(2)
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, P. R. China

References

  1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DePinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Sui X, Xu Y, Wang X, Han W, Pan H, Xiao M. Metformin: a novel but controversial drug in cancer prevention and treatment. Mol Pharm. 2015;12:3783–91.View ArticlePubMedGoogle Scholar
  4. Bansal M, Siegel E, Govindarajan R. The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX). J Clin Oncol. 2011;29:2608.View ArticleGoogle Scholar
  5. Chlebowski RT, McTiernan A, Aragaki AK, Rohan T, Wactawski-Wende J, Ipp E, et al. Metformin and breast cancer incidence in postmenopausal diabetic women in the Women’s Health Initiative (WHI). J Clin Oncol. 2011;29:1503.View ArticleGoogle Scholar
  6. Mayer MJ, Klotz LH, Venkateswaran V. The effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer. J Urol. 2017;197:1068–74.View ArticlePubMedGoogle Scholar
  7. Fan C, Wang Y, Liu Z, Sun Y, Wang X, Wei G, et al. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med. 2015;36:204–14.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Menendez JA, Quirantes-Pine R, Rodriguez-Gallego E, Cufi S, Corominas-Faja B, Cuyas E, et al. Oncobiguanides: paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget. 2014;5:2344–8.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Peng M, Su Q, Zeng Q, Li L, Liu Z, Xue L, et al. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model. Oncotarget. 2016;7:9102–17.PubMedPubMed CentralGoogle Scholar
  10. Wang ZD, Wei SQ, Wang QY. Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Am J Cancer Res. 2015;5:3339.PubMedPubMed CentralGoogle Scholar
  11. Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, Ortega A, et al. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res. 2011;31:421–6.PubMedGoogle Scholar
  12. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen C-H, et al. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci USA. 2013;110:18226–31.View ArticlePubMedGoogle Scholar
  13. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010;11:554–65.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11:9–15.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–55.View ArticlePubMedGoogle Scholar
  16. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007;13:3545–51.View ArticlePubMedGoogle Scholar
  17. Kim W-J, Kim S-K, Jeong P, Yun S-J, Cho I-C, Kim IY, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17:478–85.PubMedPubMed CentralGoogle Scholar
  18. Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, et al. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res. 2012;5:248–59.View ArticleGoogle Scholar
  19. Peng M, Huang Y, Tao T, Peng C-Y, Su Q, Xu W, et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Sci Rep. 2016;6:28611.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Busada JT, Niedenberger BA, Velte EK, Keiper BD, Geyer CB. Mammalian target of rapamycin complex 1 (mTORC1) Is required for mouse spermatogonial differentiation in vivo. Dev Biol. 2015;407:90–102.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Churchward-Venne TA, Burd NA, Phillips SM. Nutritional regulation of muscle protein synthesis with resistance exercise: strategies to enhance anabolism. Nutr Metab. 2012;9:40.View ArticleGoogle Scholar
  22. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J. 2007;403:217–34.View ArticlePubMedGoogle Scholar
  23. Yamaguchi O, Otsu K. Role of autophagy in aging. J Cardiovasc Pharmacol. 2012;60:242–7.View ArticlePubMedGoogle Scholar
  24. Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, et al. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care. 2014;37:1910–7.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Liu Z, Ren L, Liu C, Xia T, Zha X, Wang S. Phenformin induces cell cycle change, apoptosis, and mesenchymal–epithelial transition and regulates the AMPK/mTOR/p70s6k and MAPK/ERK pathways in breast cancer cells. PLoS ONE. 2015;10:e0131207.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013;123:3693–700.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Pryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015;471:307–22.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol. 2008;233:203–10.View ArticlePubMedGoogle Scholar
  29. Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, et al. Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics. Transl Oncol. 2015;8:210–6.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

Cancer Communications

ISSN: 2523-3548

Contact us